Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice.
Kujala A, Valkonen E, Sallinen H, Tuppurainen L, Laakso H, Ylä-Herttuala E, Liimatainen T, Kujala J, Jokelainen O, Sironen R, Anttila M, Ylä-Herttuala S. Kujala A, et al. Among authors: sallinen h. Front Med (Lausanne). 2022 Dec 8;9:1018208. doi: 10.3389/fmed.2022.1018208. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36569136 Free PMC article.
Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
Sopo M, Anttila M, Sallinen H, Tuppurainen L, Laurema A, Laidinen S, Hamalainen K, Tuunanen P, Koponen JK, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S. Sopo M, et al. Among authors: sallinen h. Int J Cancer. 2012 Nov 15;131(10):2394-401. doi: 10.1002/ijc.27495. Epub 2012 Mar 27. Int J Cancer. 2012. PMID: 22336998 Free article.
Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.
Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K, Heikura T, Toivanen P, Hämäläinen K, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S. Tuppurainen L, et al. Among authors: sallinen h. Hum Gene Ther Clin Dev. 2013 Mar;24(1):29-37. doi: 10.1089/humc.2013.006. Epub 2013 Apr 3. Hum Gene Ther Clin Dev. 2013. PMID: 23692381
Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI.
Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivelä A, Mäkinen P, Härmä K, Hämäläinen K, Kosma VM, Ylä-Herttuala S, Vanninen R, Sallinen H. Lindgren A, et al. Among authors: sallinen h. Eur Radiol. 2017 Sep;27(9):4002-4012. doi: 10.1007/s00330-017-4786-z. Epub 2017 Mar 13. Eur Radiol. 2017. PMID: 28289938 Free PMC article.
32 results